Lessons from in-vivo models of castration-resistant prostate cancer

Current Opinion in Urology

Volumn 23, Issue 3, 2013, Pages 214-219

  Lin, Dong ^a,b   Gout, Peter W ^b   Wang, Yuzhuo ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

androgen receptor; animal model; castration resistant prostate cancer; cellular plasticity; neuroendocrine transdifferentiation

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; ARN 509; CLUSTERIN; CUSTIRSEN; CYCLIN D1; ENZALUTAMIDE; EPI 001; HEAT SHOCK PROTEIN 90; MYC PROTEIN; ORTERONEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; STEROID 17ALPHA MONOOXYGENASE; UNCLASSIFIED DRUG;

ABLATION THERAPY; ANDROGEN SYNTHESIS; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CELL PROTECTION; CELL TRANSDIFFERENTIATION; DIMERIZATION; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; GENE DOSAGE; GENETIC VARIABILITY; IN VIVO STUDY; LIGAND BINDING; LOSS OF FUNCTION MUTATION; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STEROIDOGENESIS; TUMOR XENOGRAFT; UPREGULATION;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; LIGANDS; MALE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84876418407     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32835e9f07     Document Type: Review

References (29)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187-1197. In a phase III, double-blind, placebo-controlled, clinical trial, enzalutamide significantly prolonged the overall survival of patients with metastatic CRPC who previously received chemotherapy.
3. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13:983-992. The final analysis of the COU-AA-301 double-blind, placebo-controlled, phase III study shows that abiraterone acetate significantly prolongs the overall survival of patients with metastatic CRPC after docetaxel treatment.
4. Nelson EC, Cambio AJ, Yang JC, et al. Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostatic Dis 2007; 10: 6-14. (Pubitemid 46358906)
5. Palmgren JS, Karavadia SS, Wakefield MR. Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol 2007; 34:22-29. (Pubitemid 46161758)
6. Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011; 17:5913-5925. This study demonstrates that mechanisms of abiraterone resistance may include upregulation of CYP17A1 and upregulation of AR-Vs in LuCaP xenograft models.
7. Cai C, Chen S, Ng P, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 2011; 71:6503-6513. This study demonstrates the upregulation of CYP17A in abiraterone-treated VCaP xenografts and clinical samples following CYP17A1 inhibitor therapy, suggesting CYP17A upregulation is a mechanism underlying the resistance to treatment with abiraterone.
8. Kaku T, Hitaka T, Ojida A, et al. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg Med Chem 2011; 19:6383-6399.
9. Lubik AA, Gunter JH, Hendy SC, et al. Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res 2011; 71:5754-5764. This study provides evidence that high insulin levels can increase de novo androgen synthesis and hence contribute to castration resistance.
10. Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012; 72:1494-1503. This study demonstrates that ARN-509 has greater efficacy than enzalutamide in mouse CRPC models, providing preclinical proof-of-principle for ARN-509 as a potential drug candidate for CRPC.
11. Hu R, Lu C, Mostaghel EA, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 2012; 72:3457-3462. This study demonstrates that AR-Vs can activate gene-expression signatures distinct from full-length AR and indicates that AR-Vs-mediated signaling may be involved in the development of resistance to enzalutamide.
12. Li Y, Chan SC, Brand LJ, et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2013; 73 [Epub ahead of print]. doi: 10.1158/0008-5472.CAN-12-3630. This study demonstrates that AR-Vs resulting from AR gene rearrangement can mediate enzalutamide resistance in CRPC.
13. Watson PA, Chen YF, Balbas MD, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 2010; 107:16759-16765.
14. Andersen RJ, Mawji NR, Wang J, et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010; 17:535-546.
15. Wafa LA, Cheng H, Rao MA, et al. Isolation and identification of L-DOPA decarboxylase as a protein that binds to and enhances transcriptional activity of the androgen receptor using the repressed transactivator yeast two-hybrid system. Biochem J 2003; 375 (Pt 2):373-383. (Pubitemid 37315445)
16. Wafa LA, Cheng HL, Plaa N, et al. Carbidopa abrogates L-DOPA decarboxylase coactivation of the androgen receptor and delays prostate tumor progression. Int J Cancer 2012; 130:2835-2844.
17. Thomas C, Wafa LA, Lamoureux F, et al. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors. Prostate 2012; 72:875-885.
18. Li L, Xie H, Liang L, et al. Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage. Carcinogenesis 2012 [Epub ahead of print]. doi: 10.1093/carcin/ bgs337.
19. Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19:575-586. This study demonstrates that loss of PTEN and activation of HER kinase can decrease AR activity in a mouse prostate cancer model and in human prostate cancer xenografts.
20. Mulholland DJ, Tran LM, Li Y, et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 2011; 19:792- 804. This study demonstrates that PTEN loss can suppress AR signaling and that prostate cancer development can occur in the absence of robust AR signaling.
21. Wang J, Kobayashi T, Floc'h N, et al. B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res 2012; 72:4765-4776. This study demonstrates that Myc pathway activation is an important consequence of activation of PI3K-AKT-mTOR and MAPK signaling in a GEM model.
22. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954. (Pubitemid 34716871)
23. Cho NY, Choi M, Kim BH, et al. BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer 2006; 119:1858-1862. (Pubitemid 44356843)
24. Lamoureux F, Thomas C, Yin MJ, et al. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Res 2011; 71:5838-5849.
25. Shiota M, Zardan A, Takeuchi A, et al. Clusterin mediates TGF-beta-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells. Cancer Res 2012; 72:5261-5272.
26. Sun Y, Wang BE, Leong KG, et al. Androgen deprivation causes epithelial- mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res 2012; 72:527-536. This study demonstrates that androgen deprivation can cause EMT, as well as increased stemness in the LuCaP35 prostate cancer xenografts.
27. Collins CC, Volik SV, Lapuk AV, et al. Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. Mol Cancer Ther 2012; 11:775-783. This study demonstrates that use of a highly clinically relevant, patient-derived prostate cancer models in combination with advanced genomic profiling techniques can lead to the identification of therapeutic targets and therapies potentially useful for personalized chemotherapy.
28. Tzelepi V, Zhang J, Lu JF, et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res 2012; 18:666-677.
29. Choi SY, Gout PW, Collins CC, Wang Y. Epithelial immune cell-like transition (EIT): a proposed transdifferentiation process underlying immune-suppressive activity of epithelial cancers. Differentiation 2012; 83:293-298.